Compare SPDR Gold Trust (GLD) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Eli Lilly And Co — how do they compare? SPDR Gold Trust trades at $384.38 (market cap $139.66B), while Eli Lilly And Co trades at $1,175 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 7.4× SPDR Gold Trust's market cap, and Eli Lilly And Co pays a 0.59% dividend while SPDR Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 74 Days and Eli Lilly And Co for 93 Days on average.
| GLD | LLY | |
|---|---|---|
Market Cap | $139.66B | $1.04T |
Volume | 9,544,773 | 3,064,878 |
52-Week High | $495.90 | $1.28K |
52-Week Low | $362.32 | $799.57 |
Typical Hold Time | 74 Days | 93 Days |
Sector | — | Health |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD, the SPDR Gold Trust ETF, is trading at $384.45 with a 2.28% daily gain, though technical indicators signal bearish momentum with 17 sell signals versus 2 buy signals. The ETF faces pressure from rising Treasury yields and a strong U.S. dollar, as highlighted in recent financial news. Key support levels are at $373-$377, while resistance sits at $380-$384. Recent market sentiment remains cautious amid Federal Reserve policy uncertainty and inflation concerns.
The outlook for GLD is mixed, with near-term headwinds from monetary policy and currency strength potentially limiting upside. However, gold's role as a hedge against inflation and global debt concerns offers long-term diversification benefits. Risks include further rate hikes and dollar appreciation, but tactical buying opportunities may emerge if support levels hold.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
